Atovaquone and Proguanil Hydrochloride 62.5 mg/1

Atovaquone and Proguanil Hydrochloride 62.5 mg/1 is a combination medication used for malaria prevention and treatment. This oral tablet is formulated to provide effective protection against malaria-causing parasites.

Atovaquone and Proguanil Hydrochloride is primarily used for the prevention and treatment of malaria. It is often prescribed for travelers to areas where malaria is prevalent. The medication works by interfering with the growth of parasites in the red blood cells, thereby helping to prevent or manage malaria infections.

Common effects of Atovaquone and Proguanil Hydrochloride may include nausea, vomiting, diarrhea, and headache. Some users might experience abdominal pain or loss of appetite. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Atovaquone and Proguanil Hydrochloride should be used with caution in individuals with severe kidney or liver problems. It is important to follow the prescribed dosage and complete the full course of treatment. Pregnant women and those with a history of severe allergic reactions to similar medications should consult their healthcare provider before use.

Atovaquone and Proguanil Hydrochloride may interact with certain medications, including antacids, metoclopramide, and drugs that affect liver enzymes. Alcohol consumption should be avoided as it may reduce the effectiveness of the medication. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.